title: Neurobehavioral consequences of cortical adaptation disruption during ontogeny.
abstract: Filtering of redundant or stable inputs is a critical function of all sensory pathways. Normal sensory gating can allow processing resources to be differentially devoted to changing or otherwise biologically significant stimuli. In olfaction, short-term odor habituation is mediated by a metabotropic glutamate receptor (mGluR)-mediated depression of afferent synapses in the piriform cortex. Given the role of early experience in shaping cortical function and anatomy, the present experiments examined the effects of chronic habituation disruption during development on behavior and local circuit anatomy. Rats were chronically intra-cerebrally infused with the mGluR group III antagonist (RS)-a-cyclopropyl-4-phosphonophenylglycine (CPPG) during early development. The results demonstrated that early onset mGluRIII blockade resulted in a long-lasting decrement in odor habituation compared to controls, evident for at least 2 weeks post-infusion offset. Odor investigation time in the youngest animals was correlated with cortical laminar thickness, though the long-lasting behavioral effect showed no such correlation. No changes in apical dendritic spine density in the piriform cortex were detected. Combined with previous work, these results suggest that sensory gating disruption during development can have both immediate and long-lasting effects on sensory-guided behavior.
authors.affiliation: Neurobehavioral Institute, Department of Zoology, University of Oklahoma, USA.
authors.forename: Heather
authors.initials: H
authors.lastname: Bell
authors.forename: Brian
authors.initials: B
authors.lastname: Chenoweth
authors.forename: Donald A
authors.initials: DA
authors.lastname: Wilson
mesh_terms: D000222:Adaptation, Physiological / Q000187:drug effects / Q000502:physiology*; D000367:Age Factors; D000818:Animals; D001522:Behavior, Animal / Q000502:physiology*; D002540:Cerebral Cortex / Q000033:anatomy & histology* / Q000187:drug effects / Q000254:growth & development*; D049229:Dendritic Spines; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005998:Glycine / Q000031:analogs & derivatives / Q000494:pharmacology; D006185:Habituation, Psychophysiologic / Q000187:drug effects / Q000502:physiology*; D008297:Male; D009812:Odorants; D009833:Olfactory Pathways / Q000187:drug effects / Q000648:ultrastructure; D055696:Olfactory Perception / Q000187:drug effects / Q000502:physiology; D051381:Rats; D020318:Rats, Long-Evans; D016622:Silver Staining / Q000379:methods; D013997:Time Factors
chemical_list: D018691:Excitatory Amino Acid Antagonists; C104331:cyclopropyl-4-phosphonophenylglycine; D005998:Glycine
references.citation: J Comp Neurol. 1991 Jul 1;309(1):129-40
references.pmid: 1894766
references.citation: J Comp Neurol. 1986 Apr 1;246(1):1-19
references.pmid: 3700712
references.citation: Brain Res. 2003 Jan 24;961(1):81-7
references.pmid: 12535779
references.citation: Learn Mem. 2005 Nov-Dec;12(6):601-5
references.pmid: 16322361
references.citation: Mol Psychiatry. 2004 Apr;9(4):417-25
references.pmid: 14981523
references.citation: Biol Psychiatry. 2007 Feb 15;61(4):482-6
references.pmid: 16460695
references.citation: Trends Neurosci. 2004 Jul;27(7):370-7
references.pmid: 15219735
references.citation: Eur J Neurosci. 2002 Oct;16(7):1325-32
references.pmid: 12405993
references.citation: Science. 1972 Jun 30;176(4042):1445-7
references.pmid: 5033647
references.citation: Learn Mem. 2008 Feb 22;15(3):117-25
references.pmid: 18299438
references.citation: Brain Res Dev Brain Res. 2005 Aug 8;158(1-2):107-10
references.pmid: 15979728
references.citation: Brain Res. 1979 Jan 26;161(1):143-9
references.pmid: 758965
references.citation: Dev Neurobiol. 2007 Dec;67(14):1891-900
references.pmid: 17874461
references.citation: Biol Psychiatry. 2003 Jul 15;54(2):121-8
references.pmid: 12873801
references.citation: Neuron. 2007 Dec 20;56(6):955-62
references.pmid: 18093519
references.citation: J Neurobiol. 1997 Oct;33(4):374-86
references.pmid: 9322155
references.citation: Psychopharmacology (Berl). 2004 Mar;172(2):187-95
references.pmid: 14615875
references.citation: Neuron. 2005 Jul 7;47(1):101-14
references.pmid: 15996551
references.citation: Mol Neurobiol. 2007 Jun;35(3):298-307
references.pmid: 17917118
references.citation: J Neurophysiol. 1998 Aug;80(2):998-1001
references.pmid: 9705487
references.citation: J Neurosci. 2004 Jan 21;24(3):652-60
references.pmid: 14736851
references.citation: J Pharmacol Exp Ther. 2007 Feb;320(2):944-50
references.pmid: 17135347
references.citation: Physiol Behav. 2001 Nov-Dec;74(4-5):589-93
references.pmid: 11790419
references.citation: J Neurosci. 2005 Mar 9;25(10):2513-7
references.pmid: 15758159
references.citation: Eur J Neurosci. 2001 Feb;13(3):633-8
references.pmid: 11168572
references.citation: J Med Genet. 2003 Apr;40(4):e42
references.pmid: 12676915
references.citation: J Neurosci Methods. 1998 Jan 31;79(1):1-4
references.pmid: 9531453
references.citation: Brain Res. 2000 Jan 24;853(2):317-22
references.pmid: 10640629
references.citation: J Neurosci. 1990 Oct;10(10):3402-12
references.pmid: 1976769
references.citation: Exp Neurol. 1967 Nov;19(3):331-45
references.pmid: 6053657
references.citation: Genomics. 1997 Sep 1;44(2):232-6
references.pmid: 9299241